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Abstract
Background: Herd protection through interruption of transmission has contributed greatly to the impact of
pneumococcal conjugate vaccines (PCVs) and may enable the use of cost-saving reduced dose schedules. To aid
PCV age targeting to achieve herd protection, we estimated which population age groups contribute most to
vaccine serotype (VT) pneumococcal transmission.
Methods: We used transmission dynamic models to mirror pre-PCV epidemiology in England and Wales, Finland,
Kilifi in Kenya and Nha Trang in Vietnam where data on carriage prevalence in infants, pre-school and school-aged
children and adults as well as social contact patterns was available. We used Markov Chain Monte Carlo methods to
fit the models and then extracted the per capita and population-based contribution of different age groups to VT
transmission.
Results: We estimated that in all settings, < 1-year-old infants cause very frequent secondary vaccine type
pneumococcal infections per capita. However, 1–5-year-old children have the much higher contribution to the
force of infection at 51% (28, 73), 40% (27, 59), 37% (28, 48) and 67% (41, 86) of the total infection pressure in E&W,
Finland, Kilifi and Nha Trang, respectively. Unlike the other settings, school-aged children in Kilifi were the dominant
source for VT infections with 42% (29, 54) of all infections caused. Similarly, we estimated that the main source of
VT infections in infants are pre-school children and that in Kilifi 39% (28, 51) of VT infant infections stem from
school-aged children whereas this was below 15% in the other settings.
Conclusion: Vaccine protection of pre-school children is key for PCV herd immunity. However, in high transmission
settings, school-aged children may substantially contribute to transmission and likely have waned much of their
PCV protection under currently recommended schedules.
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Background
Streptococcus pneumoniae is a common coloniser of the
human nasopharynx and a major cause of acute otitis
media, pneumonia, sepsis and meningitis worldwide [1,
2]. Pneumococcal conjugate vaccine (PCV) introduction
to infants [3] has helped mitigate that burden [4–6];
however, the long-term success of routine vaccination is
challenged by serotype replacement [7, 8].
Herd protection has been an integral part of the suc-
cess of PCVs [9, 10]. In particular, in high-income coun-
tries, reduced acquisition of infections with vaccine-
targeted serotypes in immunised infants and toddlers
has almost eliminated their circulation, and hence asso-
ciated disease, in the whole population. This has sup-
ported the notion that the impact of a mature
programme may be sustained by a reduced dose sched-
ule that retains the impact of the programme by main-
taining herd effects albeit at the potential cost of
reduced direct protection during infancy [11]. Indeed, it
has subsequently been shown that a booster dose sched-
ule with only a single priming dose induces largely non-
inferior post booster IgG responses, when compared to
the currently WHO recommended 2 priming and
booster dose schedule, indicating similar post booster
protection and hence the potential to sustain herd ef-
fects [12]. In 2017/2018, the UK’s Joint Committee on
Vaccination and Immunisation reviewed this evidence
and recommended the switch to a reduced 1p+1 PCV
dosing schedule for the UK [13–15]. There is, however,
limited information on the extent to which decreased
PCV protection in infancy with a reduced dose schedule
may lead to an increase in vaccine serotype circulation
in the community, particularly in infants. In a reduced
dose schedule, infants may be exposed substantially
more frequent to vaccine serotypes, which in combin-
ation with their likely reduced direct protection may lead
to a resurgent of vaccine serotype pneumococcal disease
in this age group. Quantifying the contribution of infants
and other age groups to overall pneumococcal transmis-
sion dynamics (i.e. the force of infection) would aid an
assessment of such risk.
Similar to routine vaccination programmes, PCV use
in campaigns, i.e. the immunisation of a number of birth
cohorts within a confined time window, can substantially
benefit from induced herd immunity in order to opti-
mise their efficiency. Campaigns are used either to accel-
erate the impact of PCV at introduction [16, 17] or to
implement rapid vaccination in settings, including hu-
manitarian crises, where routine infant immunisation is
interrupted or unfeasible [18]. The optimal age targeting
of such campaigns depends on a combination of factors
including maximising direct protection, targeting core
transmission groups and accommodating programmatic
considerations. In many humanitarian crises, frequent
population movement, security concerns or accessibility
and cold chain problems would complicate a multi-dose
PCV campaign approach [19]. Hence, PCV campaign de-
sign should include maximising the level of herd im-
munity achieved in order to protect the most vulnerable
age groups who will only receive partial protection from
a single dose. There is, however, limited information on
which age groups are the main drivers of pneumococcal
transmission within the population and hence warrant
targeting to help interrupt transmission [20].
Evidence on pneumococcal transmission pathways
stems largely either from assessing risk factors for colon-
isation in cross-sectional carriage surveys [21–23] or
from inferring pneumococcal transmission based on tim-
ing and geographical relatedness of serotype-specific car-
riage events, observed typically in household-based
longitudinal studies [24–27]. These suggest that house-
hold exposure and child care attendance are important
routes for pneumococcal transmission, that transmission
is driven mainly by young children rather than adults
and that infants are more likely to acquire carriage from
siblings than from their parents. Further, the near elim-
ination of vaccine serotypes within a few years after
introduction of PCV programmes in infants and toddlers
suggests a disproportional contribution of young chil-
dren in pneumococcal transmission [10]. However, none
of the studies published to date have tried to quantify
the proportional contribution of different age strata
across the population to pneumococcal transmission,
partly because of the difficulty in inferring transmission
events. We aim to address this key evidence gap.
Using mathematical modelling, we combine informa-
tion on pneumococcal carriage, local demographics and
human contact patterns from four epidemiologically dis-
tinct contexts to estimate local age-specific pneumococ-
cal transmission patterns at the population level.
Methods
Data
We reviewed the literature for countries that have re-
ported both (i) pre-PCV introduction nasopharyngeal
carriage among healthy young children (< 5 years), older
children (5–17 years) and adults (18+ years) and (ii) a sur-
vey of human contact patterns relevant to the spread of
pneumococci. From a systematic review of pre-PCV
carriage studies globally (Le Polain de Waroux O: Global
landscape of Streptococcus pneumoniae serotypes colonising
healthy individuals worldwide; a systematic review and
metaanalysis, Pers. Commun. 2016) [28], we identified 14
countries with studies that reported carriage prevalence
among healthy individuals for each of the three age groups
(Chile, Finland, Gabon, The Gambia, Israel, Kenya, Malawi,
Nigeria, Papua New Guinea, South Africa, Sweden, UK, USA
and Vietnam). Of those, we identified England, Finland, Kilifi
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in Kenya and Nha Trang in Vietnam to also have collected
data on social contact patterns [29–35]. For England, Kilifi
and Finland, age-stratified estimates of clearance rates for
pneumococcal carriage episodes were also available [34, 36–
38]. In the absence of local data for Nha Trang, we assumed
clearance rates to be similar to those observed in England
and Wales because of the similarity in carriage prevalence in
these settings. Data on pneumococcal carriage prevalence
and serotype distribution were extracted as finely age-
stratified as possible but to capture at least infants, young
children, school-aged children and adults separately. Most of
the data was collected during 2000 to 2010 with all data on
the epidemiology of pneumococcus being collected before
PCV introduction (see Tables 1 and 2). We assume that dur-
ing that time and before the introduction of PCV, the epi-
demiology of pneumococcus in the respective settings as
well as the population demographic and contact patterns re-
main unchanged during that time.
We stratify carriage prevalence by vaccine and non-
vaccine type carriage. Based on the current national pro-
grammes in the respective settings, we define vaccine
types as the serotypes targeted by PCV13 for England
and Wales (E&W) and as the serotypes targeted by
PCV10 including cross protection against type 6A for
Finland and Kilifi [18]. PCV is currently not included in
the routine infant immunisation schedule in Vietnam. In
line with an ongoing cluster-randomised trial in Nha
Trang, we chose to define vaccine types in this setting as
those serotypes targeted by PCV10 and serotype 6A [44].
Contact studies nested into carriage surveys in both
Uganda [22] and Fiji [45] have recently shown that
physical (i.e. skin to skin contact) and not conversa-
tional contacts are risk factor for pneumococcal car-
riage. This provides evidence that physical contacts
are a better proxy for contacts relevant for pneumo-
coccal transmission than the often used conversa-
tional contacts. Hence, we used reported physical
contacts (Table 1) to populate setting-specific mixing
matrices using established methods [46].
Transmission models
For each of the four settings, we used a deterministic
age-structured model that simulates the transmission dy-
namics of pneumococcal carriage for the pooled vaccine
serotype and the non-vaccine serotype groups, similar to
previous approaches [47, 48]. We assume a realistic but
static population demographic (Tables 1 and 2). The
study population is divided into susceptible (S), carriers
of vaccine serotypes VT (V), carriers of non-vaccine se-
rotypes NVT (N) and carriers of both VT and NVT at
the same time (B). Due to the pooling of serotypes, no
capsular-specific immunity following infection was in-
cluded; however, carriers of either serotype group were
unable to acquire additional infection with that group
while carrying and were at reduced susceptibility for ac-
quisition of carriage with the other serotype group (i.e.
competition). Capsular non-specific protection was as-
sumed to accrue with age to resemble a steady state
proxy for the accrual of immunity with repeated expos-
ure, and hence, we estimated the susceptibility to infec-
tion given potentially infectious contact for each setting
and each of infants, pre-school children, school children
and adults independently. The set of ordinary differential
equations that govern the model read:
S
0 ¼ − λV þ λNð ÞS þ νVV þ νNN
V
0 ¼ λV S−ζλNV−νVV þ νNB
N
0 ¼ λNS−ζλVN−νNN þ νVB
B
0 ¼ ζ λVN þ λNVð Þ− νV þ νNð ÞB:
λV ¼ βV V þ Bð Þ
λN ¼ βN N þ B:ð Þ
Age and time dependencies were omitted from the
equations to enhance readability. λ is the serotype-
group-specific force of infection. ζ, the reduction in ac-
quisition rate if carrying, was assumed to be 0.1 in ac-
cordance with estimates from model fitting to post-PCV
introduction changes [16, 48, 49]. ν represents the
serotype-group- and age-group-specific clearance rates.
β represents the age-group-specific effective contact
rates who are a multiplication of the observed contact
rates with the age-specific susceptibility to infection θ.
This model includes a number of drastic simplifications
of pneumococcal epidemiology, including that it artifi-
cially promotes the stable serotype (-group) coexistence
[50]. All models stratify the population into at least in-
fants, pre-school children, school-aged children and
adults (exact age strata in Table 2).
Table 1 Year of data collection for model parameters and references to the relevant studies in brackets thereafter
England and Wales Kilifi Nha Trang Finland
Demographics 2001/2002 [39] 2009 [40] 2006 [41] 2000 [42]
Physical contacts 2005/2006 [29] 2011 [31] 2010 [35] 2005/2006 [29]
Carriage 2001/2002 [30] 2009 [32] 2008 [43] 1994–2002 [34]
Clearance rates 2001/2002 [36] 2006–2008 [37] See E&W 2001/2002 [34, 38]
PCV product—introduction PCV7—2006
PCV13—2010
PCV10—2011 No routine PCV use PCV10—2010
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Parameter inference
Country-specific models were run to reach steady
state to replicate VT and NVT carriage prevalence
pre-PCV introduction, each model was fitted inde-
pendently using a Bayesian inference framework that
samples parameter posterior distributions using
adaptive Markov Chain Monte Carlo (MCMC) [51,
52]. The multinomial likelihood of observing the
age-dependent prevalence estimates for non-carriers,
VT carriers and NVT carriers given the model pre-
dictions was maximised by estimating the age-
specific (for < 1 year, pre-school children, school
children and adults) probability for transmission
given a potentially infectious contact. It was assumed
that in the event of carriage of both VT and NVT
simultaneously either VT or NVT would be identi-
fied at equal probability [53]. In each setting, the
probability for transmission given a potentially infec-
tious contact was estimated for the four age groups:
infants, pre-school children, school children and
adults, each stratified by VT and NVT (θ1, …, θ8).
Hence, for each setting, the likelihood of θ given the




pxVaVa θð Þ pxNaNa θð Þ pxSaSa θð Þ
where the age dependent pVa, pNa, pSa and xVa, xNa, xSa
represent the prevalence of carriage in VT, NVT and
non-carriers in the steady state of the model and the
number of observed carriage events in the data, respect-
ively, stratified into n age groups. Individuals in the
model who are dual carriers were assumed to be ob-
served as VT type carriers as dual carriage was not
ascertained in the data sets used. Age dependencies of pi
and xi were omitted for readability.
To encompass the uncertainty of the observed mixing
patterns, particularly in infants, in the model, we boot-
strapped the participants included in the mixing matrix
calculations [54]. Starting with the pool of all unique
participants to calculate the mixing matrix, every iter-
ation of the MCMC, 5 contact survey participants (about
1% of the overall sample) were randomly selected, ex-
cluded, and replaced by a set of 5 participants that were
sampled with replacement from the original pool of par-
ticipants. For each MCMC iteration, the mixing matrix
Table 2 Key model input parameters for the four settings, stratified by vaccine serotypes (VT) and non-vaccine serotypes (NVT)
where appropiate
Age Population Carriage prevalence Sample
size
Clearance rate
VT NVT VT NVT
E&W < 1 year 629,200 0.43 0.12 51 0.014 0.014
1–5 years 3,009,200 0.25 0.15 138 0.029 0.029
6–14 years 5,999,000 0.08 0.10 52 0.056 0.056
15–20 years 4,132,900 0.00 0.13 8 0.057 0.057
21–49 years 21,368,700 0.00 0.02 232 0.059 0.059
50+ 17,905,900 0.00 0.00 2 0.059 0.059
Kilifi < 1 year 9617 0.41 0.46 39 0.009 0.012
1–5 years 45,170 0.34 0.44 127 0.020 0.023
6–14 years 68,547 0.15 0.39 82 0.049 0.050
15–20 years 33,289 0.14 0.25 56 0.049 0.050
21–49 years 72,143 0.07 0.22 97 0.049 0.050
50+ 24,214 0.04 0.20 104 0.049 0.050
Finland < 1 year 56,748 0.12 0.05 400 0.022 0.022
1–5 years 284,828 0.24 0.10 412 0.022 0.022
6–17 years 764,192 0.08 0.03 86 0.033 0.033
18+ 4,130,843 0.02 0.01 263 0.033 0.033
Nha Trang < 1 year 2094 0.27 0.07 41 0.014 0.014
1–5 years 15,239 0.25 0.20 63 0.029 0.029
6–17 years 40,324 0.02 0.09 55 0.056 0.056
18–49 years 115,538 0.01 0.01 262 0.059 0.059
50+ 37,544 0.01 0.01 98 0.059 0.059
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was updated according to the current pool of mixing
survey participants. Replacing about 1% of participants
per iteration was found to allow good exploration of the
mixing matrix parameter space. MCMC convergence
was assessed through Gweke criterion, and parameter
correlation was ascertained visually.
Sensitivity analyses
In principle, both the susceptibility to pneumococcal
carriage acquisition and the transmissibility when carry-
ing can change with age. However, only one of them can
be fitted here because of identifiability limitations given
the available data. We chose to fit the susceptibility to
carriage acquisition given a potentially infectious contact
and assumed that the probability of transmitting given a
potentially infectious contact would be the same across
all age groups. This was done in order to simulate a
combination of general and pneumococcal exposure re-
lated maturation of the immune system with age, con-
sistent with previously published work [34, 48, 49, 55].
For sensitivity analyses, however, we also explored fitting
the transmissibility and assuming the susceptibility was
the same across all age groups.
We also included additional sensitivity analyses to test
the robustness of the results: (i) assuming Kilifi-like wan-
ing for the Nha Trang model, (ii) assuming all social
contacts are relevant for the spread of pneumococci and
(iii) the between serotype group competition is rather
lower (c = 0.3) than assumed at base case.
All data analyses were conducted in R 3.6.1 [56]. The
project code is available under https://github.com/Ste-
fanFlasche/Pneumo_Trans_Inf.
Results
Patterns of pneumococcal carriage in the pre-PCV era
were qualitatively similar across study sites with highest
carriage prevalence of vaccine and non-vaccine serotypes
in young children, but generally declining with increas-
ing age. In contrast to the other sites, carriage preva-
lence in adults in Kilifi remained comparatively high
among adults with 4% VT and 20% NVT carriage preva-
lence among adults older than 50 years of age. Yet, the
estimated proportion of all pneumococcal carriers who
are adults was not higher in Kilifi than in the other set-
tings because the high carriage rates in adults were
counter-balanced by the relatively small contribution of
adults to the population pyramid in Kilifi (Fig. 1).
All contact studies were well powered with 947, 890,
568 and 2002 participants from E&W, Finland, Kilifi and
Nha Trang, respectively. However, with the exception of
Kilifi, the surveys included less than 18 participating in-
fants. In all settings, the reported frequency of physical
contacts was highest within the age groups of pre-school
and school-aged children. In Kilifi, less variance in
contact frequency across ages was observed. While no
infant-to-infant contact was reported in Nha Trang and
little in Kilifi, respective contact rates were among the
highest across age groups in E&W.
In all settings, the model captured the data well (Add-
itional file 1: Fig. S1 & S2). We estimate that per year an
average person in E&W, Finland, Kilifi and Nha Trang
infects 0.4 (95% quantile of the posterior (CrI), 0.3, 0.7),
0.5 (95% CrI, 0.3, 0.7), 1.9 (95% CrI, 1.5, 2.5) and 0.4
(95% CrI, 0.2, 0.6) individuals with pneumococcal vac-
cine serotypes. However, the average person in Kilifi is
15 years old and therefore half as old as an average per-
son in the other settings. In all settings, infants exert a
disproportionally high per capita infection pressure on
the community. We estimate that the average infant
from E&W, Finland, Kilifi and Nha Trang infects 3.3
(95% CrI, 1.7, 5.8), 0.8 (95% CrI, 0.5, 1.2), 3.9 (95% CrI,
2.6, 5.4) and 1.8 (95% CrI, 0.9, 3.2) persons during their
first year of life (Fig. 2a). However, in each setting, this
represents less than 10% of the overall infection pres-
sure. Pre-school and school-aged children contribute the
majority of infections with 86% (95% CrI, 71, 94), 76%
(95% CrI, 56, 90), 80% (95% CrI, 70, 87) and 81% (95%
CrI, 59, 93) in E&W, Finland, Kilifi and Nha Trang
(Fig. 3). While among those children in E&W, Finland
and Nha Trang, the biggest contribution to the infection
pressure originates in pre-school children, in Kilifi the
group of school-aged children contributes more to the
infection pressure than pre-schoolers and we estimate
that 42% (95% CrI, 29, 54) of all vaccine serotype
pneumococcal acquisitions in the pre vaccine era in
Kilifi are transmitted from school-aged children.
We estimate that an average person in E&W, Finland,
Kilifi and Nha Trang infects 0.03 (95% CrI, 0.2, 0.4), 0.01
(95% CrI, 0.01, 0.02), 0.08 (95% CrI, 0.05, 0.11), 0.02
(95% CrI, 0.01, 0.03) infants with VTs every year. In
most settings, pre-school children exhibit the highest
per capita contribution to the infection pressure on in-
fants. We find that a pre-school child on average infects
0.30 (95% CrI, 0.11–0.53), 0.10 (95% CrI, 0.05–0.16),
0.19 (95% CrI, 0.12–0.28) and 0.17 (95% CrI, 0.09–0.28)
infants per year in E&W, Finland, Kilifi and Nha Trang
(Fig. 2b). Similarly, the proportion of infant infections
originating from pre-school and school-aged children is
72% (95% CrI, 26, 98), 63% (95% CrI, 37, 84), 81% (95%
CrI, 72, 88) and 80% (95% CrI, 55, 95), while the contri-
bution of other infants as the source of infection was
18% (0, 70) in E&W and below 4% in the other settings
(Fig. 3).
In our sensitivity analysis, we assumed that transmissi-
bility rather than susceptibility varies with age. Overall,
the results were qualitatively similar in that pre-school
children were estimated to play a key role in overall
pneumococcal transmission dynamics and in the
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Fig. 1 (See legend on next page.)
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Fig. 1 Demographic and epidemiological characteristic of the four study sites Kilifi, England and Wales (EW), Nha Trang (NT) and Finland (Fin).
The top panel shows the cumulative age distributions within each setting. The middle panel shows the cumulative distribution of carriers in the
population. The bottom panel compares the country-specific probabilities of physical contact of two specific individuals each standardised by the
respective country specific average. They grey-coloured tiles indicate no reported contacts
Fig. 2 Attribution of vaccine serotype pneumococcal infections to population age strata that cause those infections for the four study sites Kilifi,
England and Wales (EW), Nha Trang (NT) and Finland (Fin). Top panel: The top row illustrates the per capita annual number of infections in the
total population that can be attributed to the respective population age strata (x-axis). Similarly, the bottom row illustrates the proportion of
infections in the total population that can be attributed to respective age strata (x-axis). Bottom panel: The top row illustrates the per capita
annual number of infections among infants that can be attributed to the respective population age strata (x-axis). Similarly, the bottom row
illustrates the proportion of infections among infants that can be attributed to respective age strata (x-axis)
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transmission to infants, with the exception of E&W
where infants were attributed a much larger share of the
overall force of infection (Figs. S4 & S5). Further-
more, we showed that our results are not sensitive to
assuming (i) Kilifi-like clearance rates of pneumococ-
cal carriage in Nha Trang (Additional file 1: Fig. S6),
(ii) all social contacts rather than only physical con-
tacts are relevant to the transmission for pneumococci
(Additional file 1: Fig. S7) or (iii) less between serotype
group competition (Additional file 1: Fig. S8).
Discussion
In this study, we combine information on population
demographics, age-stratified pre-PCV pneumococcal
carriage prevalence and social contact patterns to esti-
mate the pneumococcal transmission dynamics in four
settings which represent low, middle and high income.
Specifically, we quantify the contribution of different age
strata to the infection pressure in the whole population
and to infants particularly. We find qualitatively similar
patterns in that the largest percentage of transmission
events, i.e. more than 75% in all settings, are likely to be
coming from pre-school and school-aged children.
While infants have the highest per capita transmission
rates, their contribution to the overall burden of
pneumococcal infections was estimated to be limited.
This is likely to be because only a small proportion of all
pneumococcal carriers fall into that age range in com-
bination with a relatively low number of transmission
relevant social contacts (i.e. physical contacts) of infants,
although there is only limited data on infant contacts.
We estimate that infants acquire the majority of their
pneumococcal infections from pre-school children; how-
ever, in Kilifi where carriage rates remained relatively
high until early adulthood, many infant infections are
likely to be acquired from older children as well.
While a number of pneumococcal transmission studies
have identified risk factors for transmission, including
pneumococcal exposure from the household [23, 27] or
day care centre attendance [21], few have investigated
the drivers of pneumococcal transmission in the overall
population. Weinberger et al. use Israeli surveillance of
IPD, carriage and vaccine uptake shortly after PCV
introduction to infer that the observed herd effect in
adults was temporally associated with high vaccination
coverage in 36–59-months old children [57]. Althouse
et al. used a longitudinal household carriage study to
infer pneumococcal transmission in the respective
Fig. 3 Contribution of different population age strata (grouped into four colours) to the vaccine type infection pressure in each age stratum
(y-axis), stratified by settings Kilifi, England and Wales (EW), Nha Trang (NT) and Finland (Fin). For example, the dominance of green in a specific
stacked bar indicates that among the vaccine type pneumococcal infections in this age group and this setting most stem from
pre-school-aged children
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Native American communities by epidemiologically link-
ing carriage episodes hierarchically to either same sero-
type carriage observed in the household, the community
or importation [24]. They similarly found that toddlers
and older children drive pneumococcal transmission and
that infants are not a key source of transmission in the
community. While our results agree with these findings,
they offer additional age-granularity, depending on the
available stratification of the contact and carriage data,
that helps with a better understanding on optimal PCV
age targeting for inducing herd effects in a population
and the advantage of relying only on cross-sectional data
on pneumococcal carriage and social contacts, which are
much easier to collect than longitudinal carriage studies
or routine surveillance.
We find that despite a higher estimated per capita
transmission rate than other age groups, infants do not
contribute substantially to the overall force of pneumo-
coccal infection. This supports that leaving infants with
inferior protection under a reduced primary dose sched-
ule [11, 12] may not substantially impair population herd
effects that are mainly maintained through protection
from the booster dose in toddlers and young children.
Furthermore, we find that infants receive their vaccine
type infections predominantly from toddlers and older
pre-school children who will retain direct protection
from PCV in a 1p+1 schedule; hence, infants should
continue to benefit indirectly from PCV vaccination, al-
though, in Kilifi, we find that substantial part of VT in-
fant infections stemmed from school-aged children and
hence may pose a risk to a reduced dose strategy in such
high transmission settings. While our findings are based
on pre-PCV epidemiology, it is likely that the kinetics of
vaccine serotype transmission change with PCV use to-
ward higher dominance of age groups not directly pro-
tected by the infant programme [45].
In Kilifi, high pneumococcal carriage prevalence ex-
tends into adulthood, similar to other high burden set-
tings in Africa [58, 59]. As a result, we estimated that
the per capita rate of pneumococcal transmission among
Kilifi adults is more than five times higher than in the
other settings. However, the contribution of adults to
the overall force of pneumococcal infection is similar,
largely because adults form a much smaller contribution
of the overall population in Kilifi. This implies that if
high carriage rates in adulthood are sustained as life ex-
pectancy increases and the proportion of adults in the
community increases, this may lead to a greater contri-
bution of unvaccinated adults to community transmis-
sion and challenge PCV herd protection in the future.
Our study comes with a number of limitations. Some
of these relate to the model structure. To maintain sim-
plicity and identifiability, we aggregated serotypes into
groups and used a model that is not “structurally
neutral”, meaning that it tends to promote the long-
term coexistence of vaccine and nonvaccine serotypes
without an explicit biological mechanism. Moreover, we
attributed changes in acquisition probabilities given ex-
posure and duration of carriage to age, while these may
in fact be at least in part attributable to exposure. These
simplifications were judged acceptable because the
model was used to fit steady state data, rather than to
make detailed dynamic predictions. Other limitations re-
late to the representativeness of the available data. While
sample size were reasonably large and their associated
uncertainty is included in the posterior distributions,
only in Kilifi and Nha Trang were both the carriage and
contact surveys conducted as a representative sample of
the same study population. This mismatch of study pop-
ulations in Finland and England and Wales could bias
our estimates in that carriage information is from adults
living in the same household as a child and hence who
are likely to be disproportionally more exposed to
pneumococci than their childless counterpart. Hence, in
these settings, the limited contribution of adults to the
infection pressure may still be an over-estimation. Fur-
ther, in none of the settings were serotyping techniques
used that could detect multiple colonisation. However,
the role of secondary colonisers for transmission is
largely unknown. If secondary, sub-dominant infections
play a limited role in transmission, this is unlikely to
alter our findings. Further, we assumed that the dual col-
onisation in our model would be observed as vaccine
type carriage; however, when we assumed that such
would be attributed to non-vaccine serotype carriage,
the results did hardly change because of the relatively
low dual colonisation prevalence. The absence of car-
riage prevalence estimates in adults presented one of the
main reasons for exclusion in our study. While there is
robust information on adult carriage in Kilifi, only a
small number of adults were tested in Nha Trang and
adult carriage information in Finland and E&W is re-
stricted to parents and as a result is likely to overesti-
mate carriage rates of the general adult population.
Furthermore, we have shown that our results are robust
to a number of alternative assumptions, including social
rather than physical contacts or alternative carriage
clearance rates. For 3 out of 4 countries, the results were
also robust to estimating age dependency of transmissi-
bility instead of susceptibility, except for E&W where in-
fants had a much larger role in transmission under this
assumption. While in contrast to susceptibility to infec-
tion there is currently no evidence for age-dependent
differences in transmissibility of pneumococci, from our
results alone, we therefore cannot rule out that infants
may play a larger role in transmission in E&W. Finally,
one of our main outcomes is the quantification of the
role of infants in pneumococcal transmission. However,
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reported information on infant contacts was rare in the
studies evaluated. In three of the study sites, only a
handful of infants were included in the social contact
survey. To account for this and the wider uncertainty in
the mixing matrices, we bootstrapped the mixing matri-
ces during the fitting procedure. However, because the
surveys were largely filled in by the infant’s mothers, in-
formation on contacts during nursery attendance is
missing. While childcare attendance rates during the
first year of life is likely rather low in Kilifi and Nha
Trang [60], we may under-estimate infant contact rates
in Finland and E&W.
Conclusion
In conclusion, we provide a framework for inference of
age-stratified population transmission patterns from
cross-sectional data on pneumococcal carriage preva-
lence and social contacts, which adds to the evidence
base supporting toddlers and young children as the key
drivers of pneumococcal transmission in many settings.
We also highlight the potential role of school-aged chil-
dren and young adults as key vaccine serotype transmit-
ters, particularly in settings with high carriage rates in
these age groups. The important contribution that these
individuals play may in part explain the reduced herd ef-
fects observed in some settings if protection against car-
riage acquisition from a PCV infant programme wanes
to leave these age groups unprotected [61]. Our results
support the notion that a reduced dose 1p+1 schedule is
likely to sustain herd effects in settings with low residual
VT carriage with minimal increased risk for infants be-
fore receipt of their booster dose. While our approach
allows approximation of transmission on a population
level from cross-sectional data, advances in phylogenetic
inference may soon allow to substantially increase the
specificity of epidemiological linkage by using genomic
sequencing, which in turn will allow for better estimates
of pneumococcal transmission dynamics.
Supplementary information
Supplementary information accompanies this paper at https://doi.org/10.
1186/s12916-020-01601-1.




SF designed the study conducted the analyses and wrote the first draft. AP,
JO and ML critically reviewed the analyses and all authors contributed to the
writing of the submitted manuscript. All authors read and approved the final
manuscript.
Funding
SF is supported by a Sir Henry Dale Fellowship jointly funded by the
Wellcome Trust and the Royal Society (Grant number 208812/Z/17/Z). AP is
supported by the Bill and Melinda Gates Foundation (OPP1139859). JO is
supported by the National Institute for Health Research (NIHR) Global Health
Research Unit on Mucosal Pathogens using UK aid from the UK Government.
The views expressed in this publication are those of the author(s) and not
necessarily those of the NIHR or the Department of Health and Social Care.
Availability of data and materials
All data and code is available at https://github.com/StefanFlasche/Pneumo_
Trans_Inf.
Ethics approval and consent to participate
The study only comprises of secondary analysis of published data and hence




The authors declare that they have no competing interests.
Author details
1Centre for Mathematical Modelling of Infectious Diseases, Department of
Infectious Disease Epidemiology, London School of Hygiene & Tropical
Medicine, Keppel Street, London, UK. 2Center for Communicable Disease
Dynamics, Department of Epidemiology and Department of Immunology
and Infectious Diseases, Harvard School of Public Health, 677 Huntington
Avenue, Boston, MA, USA.
Received: 10 December 2019 Accepted: 21 April 2020
References
1. O’Brien KL, Wolfson LJ, Watt JP, Henkle E, Deloria-Knoll M, McCall N, et al.
Burden of disease caused by Streptococcus pneumoniae in children younger
than 5 years: global estimates. Lancet. 2009;374(9693):893–902 [cited 2013
Dec 15]Available from: http://linkinghub.elsevier.com/retrieve/pii/S01406736
09612046.
2. Wahl B, O’Brien KL, Greenbaum A, Majumder A, Liu L, Chu Y, et al. Burden
of Streptococcus pneumoniae and Haemophilus influenzae type b disease
in children in the era of conjugate vaccines: global, regional, and national
estimates for 2000–15. Lancet Glob Heal. 2018;6(7):e744–57 Available from:
https://linkinghub.elsevier.com/retrieve/pii/S2214109X1830247X.
3. International Vaccine Access Center - Johns Hokins Bloomberg School of
Public Health. Global PCV introduction status [Internet]. 2015 [cited 2016
Sep 5]. Available from: http://view-hub.org/viz/.
4. Mackenzie GA, Hill PC, Sahito SM, Jeffries DJ, Hossain I, Bottomley C, et al.
Impact of the introduction of pneumococcal conjugate vaccination on
pneumonia in The Gambia: population-based surveillance and case-control
studies. Lancet Infect Dis. 2017;17(9):965–73 Available from: http://
linkinghub.elsevier.com/retrieve/pii/S1473309917303213.
5. Ladhani SN, Collins S, Djennad A, Sheppard CL, Borrow R, Fry NK, et al.
Rapid increase in non-vaccine serotypes causing invasive pneumococcal
disease in England and Wales, 2000–17: a prospective national
observational cohort study. Lancet Infect Dis. 2018; [cited 2018 Feb 7].
Available from: http://linkinghub.elsevier.com/retrieve/pii/S14733099183
00525.
6. Ben-Shimol S, Givon-Lavi N, Leibovitz E, Raiz S, Greenberg D, Dagan R. Near-
elimination of otitis media caused by 13-valent pneumococcal conjugate
vaccine (PCV) serotypes in Southern Israel shortly after sequential
introduction of 7-valent/13-valent PCV. Clin Infect Dis. 2014;59(12):1724–32
[cited 2014 Sep 1]. Available from: http://cid.oxfordjournals.org/content/
early/2014/08/25/cid.ciu683.abstract.
7. Weinberger DM, Malley R, Lipsitch M. Serotype replacement in disease after
pneumococcal vaccination. Lance. 2011;378:1962–73.
8. Lewnard JA, Hanage WP. Making sense of differences in pneumococcal
serotype replacement. Lancet Infect Dis. 2019; [cited 2019 Feb 4]. Available
from: https://www.sciencedirect.com/science/article/pii/S1473309918306601
?via%3Dihub.
9. Flasche S. The scope for pneumococcal vaccines that do not prevent
transmission. Vaccine. 2017;35(45):6043–6 Available from: http://linkinghub.
elsevier.com/retrieve/pii/S0264410X17313269.
Flasche et al. BMC Medicine          (2020) 18:129 Page 10 of 12
10. Feikin DR, Kagucia EW, Loo JD, Link-Gelles R, Puhan MA, Cherian T, et al.
Serotype-specific changes in invasive pneumococcal disease after
pneumococcal conjugate vaccine introduction: a pooled analysis of
multiple surveillance sites. PLoS Med. 2013;10(9):e1001517 [cited 2014 Jul
16]. Available from: http://dx.plos.org/10.1371/journal.pmed.1001517. Viboud
C, editor.
11. Flasche S, Van Hoek AJ, Goldblatt D, Edmunds WJ, O’Brien KL, Scott JAG,
et al. The potential for reducing the number of pneumococcal conjugate
vaccine doses while sustaining herd immunity in high-income countries.
PLoS Med. 2015;12(6):e1001839 Available from: http://dx.plos.org/10.1371/
journal.pmed.1001839.
12. Goldblatt D, Southern J, Andrews NJ, Burbidge P, Partington J, Roalfe L,
et al. Pneumococcal conjugate vaccine 13 delivered as one primary and
one booster dose (1 + 1) compared with two primary doses and a booster
(2 + 1) in UK infants: a multicentre, parallel group randomised controlled
trial. Lancet Infect Dis. 2017;3099(17):1–9 Available from: http://linkinghub.
elsevier.com/retrieve/pii/S1473309917306540.
13. Joint Committee on Vaccination and Immunisation UK. Minute of the
meeting on 04 October 2017 [Internet]. 2017 [cited 2018 May 18]. Available
from: https://app.box.com/s/iddfb4ppwkmtjusir2tc/file/247634612957.
14. Joint Committee on Vaccination and Immunisation. Minutes of the meeting
on Thursday 10 may 2018 [Internet]. 2018 [cited 2018 Jul 18]. Available
from: https://app.box.com/s/1mrhw4tnughfvbbvujt5thww5f0mjhpv/file/305
778551993.
15. Joint Committee on Vaccination and Immunisation UK. Minutes of the
meeting on 06 June 2018 [Internet]. 2018 [cited 2018 Jul 18]. Available
from: https://app.box.com/s/iddfb4ppwkmtjusir2tc/file/305779572165.
16. Flasche S, Ojal J, Le Polain de Waroux O, Otiende M, O’Brien KL, Kiti M, et al.
Assessing the efficiency of catch-up campaigns for the introduction of
pneumococcal conjugate vaccine: a modelling study based on data from
PCV10 introduction in Kilifi, Kenya. BMC Med. 2017;15(1):113 Available from:
http://bmcmedicine.biomedcentral.com/articles/10.1186/s12916-017-0882-9.
17. World Health Organization. Pneumococcal vaccines WHO position paper--
2012. Wkly Epidemiol Rec. 2012;87(14):129–44 Available from: http://www.
ncbi.nlm.nih.gov/pubmed/24340399.
18. World Health Organization. Meeting of the Strategic Advisory Group of
Experts on immunization, October 2017 – conclusions and
recommendations. Wkly Epidemiol Rec. 2017;48(92):729–48.
19. World Health Organization. Vaccination in acute humanitarian emergencies
- a framework for decision making [Internet]. 2017. Available from: http://
apps.who.int/iris/bitstream/handle/10665/255575/WHO-IVB-17.03-eng.
pdf?sequence=1.
20. van Zandvoort K, Checchi F, Diggle E, Eggo RM, Gadroen K, Mulholland K,
et al. Pneumococcal conjugate vaccine use during humanitarian crises.
Vaccine. 2019; [cited 2019 Sep 25]. Available from: https://www.
sciencedirect.com/science/article/pii/S0264410X19312472?via%3Dihub.
21. Huang SS, Finkelstein JA, Lipsitch M. Modeling community- and individual-
level effects of child-care center attendance on pneumococcal carriage. Clin
Infect Dis. 2005;40(9):1215–22 Available from: https://doi.org/10.1086/
428580.
22. le Polain de Waroux O, Flasche S, Kucharski AJ, Langendorf C, Ndazima D,
Mwanga-Amumpaire J, et al. Identifying human encounters that shape the
transmission of Streptococcus pneumoniae and other acute respiratory
infections. Epidemics. 2018; Available from: http://linkinghub.elsevier.com/
retrieve/pii/S1755436518300446.
23. Heinsbroek E, Tafatatha T, Chisambo C, Phiri A, Mwiba O, Ngwira B, et al.
Pneumococcal acquisition among infants exposed to HIV in rural Malawi: a
longitudinal household study. Am J Epidemiol. 2016;183(1):70–8 Available
from: http://aje.oxfordjournals.org/lookup/doi/10.1093/aje/kwv134.
24. Althouse BM, HAMMITT LL, GRANT L, WAGNER BG, REID R, LARZELERE-
HINTON F, et al. Identifying transmission routes of Streptococcus
pneumoniae and sources of acquisitions in high transmission communities.
Epidemiol Infect. 2017;145(13):2750–8 Available from: https://www.
cambridge.org/core/product/identifier/S095026881700125X/type/journal_
article.
25. Leino T, Auranen K, Jokinen J, Leinonen M, Tervonen P, Takala AK.
Pneumococcal carriage in children during their first two years: important
role of family exposure. Pediatr Infect Dis J. 2001;20(11):1022–7 Available
from: http://www.ncbi.nlm.nih.gov/pubmed/11734705.
26. Shiri T, Auranen K, Nunes MC, Adrian PV, van Niekerk N, de Gouveia L, et al.
Dynamics of pneumococcal transmission in vaccine-naive children and their
HIV-infected or HIV-uninfected mothers during the first 2 years of life. Am J
Epidemiol. 2013;178(11):1629–37 [cited 2014 Jan 30]. Available from: http://
aje.oxfordjournals.org/cgi/doi/10.1093/aje/kwt200.
27. Erästö P, Hoti F, Granat SM, Mia Z, Mäkelä PHH, Auranen K. Modelling multi-
type transmission of pneumococcal carriage in Bangladeshi families.
Epidemiol Infect. 2010;138(6):861–72 [cited 2010 Aug 20]. Available from:
http://journals.cambridge.org/abstract_S0950268809991415.
28. Chen C, Cervero Liceras F, Flasche S, Sidharta S, Yoong J, Sundaram N, et al.
Effect and cost-effectiveness of pneumococcal conjugate vaccination: a
global modelling analysis. Lancet Glob Heal. 2019;7(1):e58–67 [cited 2018
Dec 18]. Available from: https://www.sciencedirect.com/science/article/pii/
S2214109X18304224?via%3Dihub.
29. Mossong J, Hens N, Jit M, Beutels P, Auranen K, Mikolajczyk R, et al. Social
contacts and mixing patterns relevant to the spread of infectious diseases.
PLoS Med. 2008;5(3):e74 [cited 2010 Jul 15]. Available from: http://dx.plos.
org/10.1371/journal.pmed.0050074. Riley S, editor.
30. Hussain M, Melegaro A, Pebody RG, George R, Edmunds WJ, Talukdar R,
et al. A longitudinal household study of Streptococcus pneumoniae
nasopharyngeal carriage in a UK setting. Epidemiol Infect. 2005;133(5):891–8
Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=
2870321&tool=pmcentrez&rendertype=abstract.
31. Kiti MC, Kinyanjui TM, Koech D, Munywoki PK, Medley GF, Nokes DJ.
Quantifying age-related rates of social contact using diaries in a rural coastal
population of Kenya. PLoS One. 2014;9(8):e104786 [cited 2014 Dec 17].
Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=
4134222&tool=pmcentrez&rendertype=abstract.
32. Hammitt LL, Akech DO, Morpeth SC, Karani A, Kihuha N, Nyongesa S, et al.
Population effect of 10-valent pneumococcal conjugate vaccine on
nasopharyngeal carriage of Streptococcus pneumoniae and non-typeable
Haemophilus influenzae in Kilifi, Kenya: findings from cross-sectional carriage
studies. Lancet Global Health. 2014:e397–405 [cited 2014 Aug 7]. Available
from: http://linkinghub.elsevier.com/retrieve/pii/S2214109X14702244.
33. Yoshida LM, Suzuki M, Yamamoto T, Nguyen HA, Nguyen CD, Nguyen AT,
et al. Viral pathogens associated with acute respiratory infections in central




34. Nurhonen M, Cheng AC, Auranen K. Pneumococcal transmission and
disease in silico: a microsimulation model of the indirect effects of
vaccination. PLoS One. 2013;8(2):e56079 [cited 2013 Mar 5]. Available from:
http://www.ncbi.nlm.nih.gov/pubmed/23457504.
35. Le Polain De Waroux O, Edmunds WJ, Takahashi K, Ariyoshi K, Mulholland
EK, Goldblatt D, et al. Predicting the impact of pneumococcal conjugate
vaccine programme options in Vietnam. Hum Vaccin Immunother. 2018;
14(8):1939–47 [cited 2018 Oct 13]. Available from: https://www.tandfonline.
com/doi/full/10.1080/21645515.2018.1467201.
36. Melegaro A, Gay NJ, Medley GF. Estimating the transmission parameters of
pneumococcal carriage in households. Epidemiol Infect. 2004;132(3):433–41
Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=
2870123&tool=pmcentrez&rendertype=abstract.
37. Lipsitch M, Abdullahi O, D’Amour A, Wen X, Weinberger DM, Tchetgen ET,
et al. Estimating rates of carriage acquisition and clearance and competitive
ability for pneumococcal serotypes in Kenya with a Markov transition mode.
Epidemiology. 2012;23(4):1–10 [cited 2012 Mar 27]. Available from: http://
www.ncbi.nlm.nih.gov/pubmed/22441543.
38. Hoti F, Erästö P, Leino T, Auranen K. Outbreaks of Streptococcus pneumoniae
carriage in day care cohorts in Finland - implications for elimination of
transmission. BMC Infect Dis. 2009;9(1):102 [cited 2010 Aug 20]. Available
from: http://www.biomedcentral.com/1471-2334/9/102.
39. Office for National Statistics. Population estimates for the UK [Internet]. 2018
[cited 2018 Dec 18]. Available from: https://www.ons.gov.uk/.
40. Scott JAG, Bauni E, Moisi JC, Ojal J, Gatakaa H, Nyundo C, et al. Profile: The
Kilifi Health and Demographic Surveillance System (KHDSS). Int J Epidemiol.
2012;41(3):650–7 [cited 2013 Nov 1]. Available from: http://www.ncbi.nlm.
nih.gov/pubmed/22544844.
41. Yanai H, Thiem VD, Matsubayashi T, Huong VTT, Suzuki M, Mai LP, et al. The
Khanh Hoa Health Project: characterization of study population and field
site development for clinical epidemiological research on emerging and re-
emerging infectious diseases. Trop Med Health. 2007;35(2):61–3 Available
from: http://joi.jlc.jst.go.jp/JST.JSTAGE/tmh/35.61?from=CrossRef.
Flasche et al. BMC Medicine          (2020) 18:129 Page 11 of 12
42. Statistics Finland. Population estimates for Finland [Internet]. 2018 [cited
2018 Dec 19]. Available from: https://www.stat.fi/tup/suoluk/suoluk_vaesto_
en.html.
43. Talarico CA. Epidemiologic characteristics of colonizing Streptococcus
pneumoniae in Vietnam and implications for population vaccination
[Internet]: The University of Michigan; 2009. Available from: https://
deepblue.lib.umich.edu/bitstream/handle/2027.42/64706/ctalaric_1.
pdf?sequence=1&isAllowed=y.
44. Clinicaltrials.org. Evaluation of PCV schedules in a naive population in
Vietnam [Internet]. [cited 2019 Sep 20]. Available from: https://clinicaltrials.
gov/ct2/show/NCT02961231.
45. Neal EFG, Flasche S, Nguyen CD, Ratu FT, Dunne EM, Koyamaibole L, et al.
Associations between ethnicity, social contact, and pneumococcal carriage
three years post-PCV10 in Fiji. Vaccine. 2019; [cited 2019 Nov 21]. Available
from: https://www.sciencedirect.com/science/article/pii/S0264410X19314033.
46. Wallinga J, Teunis P, Kretzschmar M. Using data on social contacts to
estimate age-specific transmission parameters for respiratory-spread
infectious agents. Am J Epidemiol. 2006;164(10):936–44 [cited 2013 Aug 8].
Available from: https://doi.org/10.1093/aje/kwj317.
47. Lipsitch M. Vaccination against colonizing bacteria with multiple serotypes.
Proc Natl Acad Sci U S A. 1997;94(12):6571–6 [cited 2014 Sep 12]. Available
from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=21091
&tool=pmcentrez&rendertype=abstract.
48. Melegaro A, Choi YH, George R, Edmunds WJ, Miller E, Gay NJ. Dynamic
models of pneumococcal carriage and the impact of the heptavalent
pneumococcal conjugate vaccine on invasive pneumococcal disease. BMC
Infect Dis. 2010;10(1):90 [cited 2011 Nov 24]. Available from: http://www.
biomedcentral.com/1471-2334/10/90.
49. Choi YH, Jit M, Gay N, Andrews N, Waight PA, Melegaro A, et al. 7-valent
pneumococcal conjugate vaccination in England and Wales: is it still
beneficial despite high levels of serotype replacement? PLoS One. 2011;
6(10):e26190 [cited 2011 Oct 17]. Available from: http://www.
pubmedcentral.nih.gov/articlerender.fcgi?artid=3193519&tool=
pmcentrez&rendertype=abstract. Borrow R, editor.
50. Lipsitch M, Colijn C, Cohen T, Hanage WP, Fraser C. No coexistence for free:
neutral null models for multistrain pathogens. Epidemics. 2009;1(1):2 [cited




51. Hastings WK. Monte Carlo sampling methods using Markov chains and their
applications. Biometrika. 1970;57(1):97 Available from: https://www.jstor.org/
stable/2334940?origin=crossref.
52. Dureau J, Kalogeropoulos K, Baguelin M. Capturing the time-varying drivers
of an epidemic using stochastic dynamical systems. Biostatistics. 2013;14(3):
541–55.
53. Kamng’ona AW, Hinds J, Bar-Zeev N, Gould KA, Chaguza C, Msefula C, et al.
High multiple carriage and emergence of Streptococcus pneumoniae vaccine
serotype variants in Malawian children. BMC Infect Dis. 2015;15(1):234
Available from: http://bmcinfectdis.biomedcentral.com/articles/10.1186/s12
879-015-0980-2.
54. Baguelin M, Flasche S, Camacho A, Demiris N, Miller E, Edmunds WJJ.
Assessing optimal target populations for influenza vaccination programmes:
an evidence synthesis and modelling study. PLoS Med. 2013;10(10):
e1001527 [cited 2013 Nov 25]. Available from: http://www.pubmedcentral.
nih.gov/articlerender.fcgi?artid=3793005&tool=pmcentrez&rendertype=
abstract. Leung GM, editor.
55. Cobey S, Lipsitch M. Niche and neutral effects of acquired immunity permit
coexistence of pneumococcal serotypes. Science (80- ). 2012;335(6074):
1376–80 Available from: http://www.ncbi.nlm.nih.gov/pubmed/22383809.
56. R Core Team. R: a language and environment for statistical computing
[internet]. Vienna: R Foundation for Statistical Computing; 2018. Available
from: http://www.r-project.org.
57. Weinberger DM, Pitzer VE, Regev-Yochay G, Givon-Lavi N, Dagan R. Association
between the decline in pneumococcal disease in unimmunized adults and
vaccine-derived protection against colonization in toddlers and preschool-
aged children. Am J Epidemiol. 2019;188(1):160–8 [cited 2019 Sep 20].
Available from: https://academic.oup.com/aje/article/188/1/160/5193516.
58. Roca A, Hill PC, Townend J, Egere U, Antonio M, Bojang A, et al. Effects of
community-wide vaccination with PCV-7 on pneumococcal nasopharyngeal
carriage in the Gambia: a cluster-randomized trial. PLoS Med. 2011;8(10):
e1001107 [cited 2011 Nov 1]. Available from: http://www.pubmedcentral.
nih.gov/articlerender.fcgi?artid=3196470&tool=pmcentrez&rendertype=
abstract.
59. Usuf E, Bottomley C, Adegbola RA, Hall A. Pneumococcal carriage in sub-
saharan Africa-a systematic review. PLoS One. 2014;9(1):e85001 [cited 2014
Jan 29]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/24465464.
60. Toizumi M, Yoshida L-M, Suzuki M, Nguyen HAT, Pinsent A, Dang DA, et al.
Infant contact in day-care centres in Vietnam: a cross-sectional study to
understand infant infection risk. Wellcome Open Res. 2019;4:75 Available
from: https://wellcomeopenresearch.org/articles/4-75/v1.
61. Lourenço J, Obolski U, Swarthout TD, Gori A, Bar-Zeev N, Everett D, et al.
Determinants of high residual post-PCV13 pneumococcal vaccine type
carriage in Blantyre, Malawi: a modelling study. bioRxiv. 2019; Available
from: https://www.biorxiv.org/content/10.1101/477695v2.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Flasche et al. BMC Medicine          (2020) 18:129 Page 12 of 12
